Medication Approvals

On March 6, 2015, the U.S. Food and Drug Administration (FDA) announced the approval of Zarxio® (filgrastim-sndz) as a biosimilar to Neupogen®. The formulation of Zarxio differs from that of U.S.-licensed Neupogen in one inactive component, and a review of evidence demonstrated that “there are no clinically meaningful differences between Zarxio and U.S.-licensed Neupogen,” according to an FDA announcement. In addition, the agency notes that more biosimilar treatment options are expected to be approved in the future.

Comments

There are currently no comments, be the first to post one.

Post Comment

Only registered users may post comments.